Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients

Transplantation

Volumn 88, Issue 4, 2009, Pages 514-520

  Cooper, Matthew ^a   Deering, Kathleen L ^b   Slakey, Douglas P ^c   Harshaw, Qing ^b   Arcona, Stephen ^d   McCann, Erin L ^e,f   Rasetto, Flavia A ^f   Florman, Sander S ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Health Economics and Outcomes Research   (United States)

^c TULANE UNIVERSITY MEDICAL CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

Author keywords

Gastrointestinal adverse events; Mycophenolate mofetil; Mycophenolate sodium; Rejection risk.; Renal transplant

Indexed keywords

ALEMTUZUMAB; ANTIBODY; BASILIXIMAB; CYCLOSPORIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME; URINARY TRACT INFECTION; VIRUS INFECTION;

AGED; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL TRACT; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TABLETS, ENTERIC-COATED;

EID: 70349160011     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b0e65e     Document Type: Article

References (19)

1. Kitchin JE, Pomeranz MK, Pak G, et al. Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 1997; 37: 445.
2. Mycophenolate mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate Mofetil Study Group. Am J Kidney Dis 1999; 34: 296.
3. Arns W. Noninfectious gastrointestinal (GI) complications of myco-phenolic acid therapy: A consequence of local GI toxicity? Transplant Proc 2007; 39: 88.
4. Salvadori M, Holzer H, de Mattos A, et al; The ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231.
5. Ciancio G, Burke GW, Gaynor JJ, et al. Randomized trial of mycophe-nolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/ thymoglobulin: One year follow-up. Transplantation 2008; 86: 67.
6. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006; 82: 102.
7. Tierce JC, Petrilla AA, Kilburg A, et al. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 2005; 19: 779.
8. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381.
9. Budde K, Knoll G, Curtis J, et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophe-nolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Clin Nephrol 2006; 66: 103.
10. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management. Drug Saf 2001; 24: 645.
11. Budde K, Knoll G, Chan L,et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004; 4: 237.
12. Bolin P, Tanriover B, Zibari GB, et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from myco-phenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 2007; 84: 1443.
13. Chan L, Mulgaonkar S, Walker R, et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006; 81: 1290.
14. Pietruck F, Abbud-Filho M, Vathsala A, et al. Conversion from myco-phenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: Pooled results from three international, multicenter studies. Transplant Proc 2007; 39: 103.
15. Davies NM, Grinyo J, Heading R, et al. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: A reappraisal. Nephrol Dial Transplant 2007; 22: 2440.
16. Hardinger KL, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with my-cophenolate mofetil. Transpl Int 2004; 17: 609.
17. Hardinger KL, Bloomer T, Murillo D. Adverse drug reaction driven immunosuppressive drug manipulations: A single-center comparison of enteric-coated mycophenolate sodium vs. mycophenolate mofetil. Clin Transplant 2008; 22: 555.
18. Pelletier RP, Henry ML, Rajab A, et al. Clinical outcomes of renal transplant recipients treated with enteric-coated mycophenolic acid vs. mycophenolate mofetil as a switch agent using a primary steroid-free rapamune and micro-emulsion cyclosporine protocol. Clin Transplant 2007; 21: 532.
19. Pelletier RP, Henry ML, Bumgardner GL, et al. The impact of myco-phenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200.